# Intraductal papillary mucinous neoplasm and other pancreatic cystic precursors

Source: https://onco.cc/cancers/ipmn-cystic-precursors/  
OnCo record `ipmn-cystic-precursors` (Cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Intraductal papillary mucinous neoplasms are fluid-filled growths in the pancreatic ducts that make mucus and can slowly turn into pancreatic cancer, one of the few chances to catch pancreatic cancer before it starts. Most are watched with scans for years, and surgery is reserved for the ones with warning signs such as a widened main duct, a solid nodule inside the cyst or jaundice.

## Summary

Intraductal papillary mucinous neoplasm (IPMN) is a mucin-producing epithelial neoplasm growing within the main pancreatic duct, its side branches or both. Main-duct and mixed-type IPMNs carry a substantial risk of high-grade dysplasia or invasive cancer at resection; branch-duct IPMNs, the commonest incidental cyst, progress in only a small minority over years. Mucinous cystic neoplasms (MCNs) occur almost only in women, in the body or tail, and have ovarian-type stroma; serous cystadenomas are benign and linked to VHL; solid pseudopapillary neoplasms are low-grade tumours of young women driven by CTNNB1. IPMNs carry KRAS and GNAS mutations early and acquire TP53, CDKN2A and SMAD4 changes as they progress, and cyst fluid analysis for CEA, glucose and mutations helps tell mucinous from non-mucinous cysts.

Management follows the international Fukuoka and Kyoto (2024) guidelines and the European consensus. High-risk stigmata (obstructive jaundice from a head cyst, an enhancing mural nodule of 5 mm or more, main duct of 10 mm or more, or positive cytology) call for resection in fit patients. Worrisome features (cyst of 3 cm or more, thickened enhancing wall, main duct 5 to 9 mm, smaller nodules, rapid growth, raised CA 19-9, new diabetes, pancreatitis) lead to endoscopic ultrasound with fluid sampling and closer surveillance. Cysts without these features are followed with MRI or endoscopic ultrasound at intervals set by size, and the question of when surveillance can stop in older patients with stable small cysts is unresolved.

Surgery is pancreatoduodenectomy or distal pancreatectomy; invasive cancer arising in an IPMN is staged and treated as pancreatic ductal adenocarcinoma, though colloid-type invasive IPMN carcinomas have a better outcome, and the remaining pancreas needs continued surveillance because IPMN is a field disease. Research aims at cyst fluid and blood biomarkers that separate the cysts that will progress from the many that never will, at artificial intelligence reading of scans, and at the link between new-onset diabetes and early pancreatic cancer.

## Fields

- Kind: Cancer
- Last checked: 2026-09-18
- Also known as: IPMN; Pancreatic cyst; Mucinous cystic neoplasm; MCN; Pancreatic cystic neoplasm; Precancerous pancreatic cyst
- Tags: subtype-page; gastrointestinal
- Group: gastrointestinal
- Burden: Pancreatic cysts are found incidentally on scans in a few percent of adults and in a much larger share of people over 70; most are harmless, but intraductal papillary mucinous neoplasms and mucinous cystic neoplasms can progress to pancreatic cancer, and IPMNs are the precursor of a minority of pancreatic cancers.
- Subtypes: Main-duct IPMN (high risk of high-grade dysplasia or invasive PDAC; resection in fit patients); Branch-duct IPMN without worrisome features (surveillance); Branch-duct IPMN with worrisome features or high-risk stigmata (endoscopic ultrasound, resection); Invasive carcinoma arising in an IPMN (tubular or colloid type; treated as ductal PDAC); Mucinous cystic neoplasm (women, body or tail, ovarian-type stroma; resection); Serous cystadenoma (benign; VHL association) and solid pseudopapillary neoplasm (CTNNB1; resection)
- Biomarkers: MRI with MRCP or pancreas-protocol CT: cyst size, main duct diameter, mural nodules, growth rate; Endoscopic ultrasound with cyst fluid CEA, glucose, cytology and KRAS, GNAS and other mutations; Serum CA 19-9 (worrisome feature when raised); New-onset diabetes or pancreatitis (worrisome features); Histological subtype of resected IPMN (gastric, intestinal, pancreatobiliary) and grade of dysplasia; TP53, SMAD4 and CDKN2A alterations in cyst fluid (investigational markers of progression)

## Sections of this record

The page is a hub with ten sections in reading order; large sections have their own page. The same plan as JSON: https://onco.cc/api/v1/cancers/ipmn-cystic-precursors/sections.json

- Overview (on the hub): The TL;DR, the family this cancer belongs to, the organ, who gets it and what the state of the art is. https://onco.cc/cancers/ipmn-cystic-precursors/#overview [4 state-of-the-art points]
- Types and stages (on the hub): Anatomy, the subtypes and how they differ, how it is staged, and where advanced disease spreads. https://onco.cc/cancers/ipmn-cystic-precursors/#what-it-is [6 subtypes]
- Symptoms and diagnosis (on the hub): How this cancer shows itself, how the diagnosis is confirmed, and the biomarkers clinicians test for. https://onco.cc/cancers/ipmn-cystic-precursors/#finding-it [6 biomarkers]
- Treatment (on the hub): The standard of care by setting, the medicines, surgery and radiotherapy named in it, and the regimens behind them. https://onco.cc/cancers/ipmn-cystic-precursors/#treating-it [5 settings, 3 decisions with options]
- Trials and papers (on the hub): Trials recruiting now, the landmark trials, the trials held by this cancer's subtypes, the key papers and what they mean, the latest literature, and the milestones year by year. https://onco.cc/cancers/ipmn-cystic-precursors/#evidence [3 trials, 16 key papers, 6 milestones]
- Biology and targets (on the hub): The molecular landscape: the targets and how often each appears, the pathways, the mechanics stages and the preclinical models. https://onco.cc/cancers/ipmn-cystic-precursors/#science [2 targets, 3 pathways]
- Countries and centres (own page): Cases by country, the UK and NHS pathway and other country lenses, the expert centres with trials on record, and the centres named on this cancer's subtypes. https://onco.cc/cancers/ipmn-cystic-precursors/where-you-are/
- Decisions and support (on the hub): The decisions you may face, the aids that walk through them, the warnings on record, the first sixty days and the questions to ask. https://onco.cc/cancers/ipmn-cystic-precursors/#living-with-it [16 questions, 2 red cards]
- Pipeline and open problems (own page): Everything in development, the medicines held by this cancer's subtypes, the open problems and what is being done about them, the roadmaps, and what changed on this record. https://onco.cc/cancers/ipmn-cystic-precursors/coming/ [2 medicines, 2 trials, 5 ideas, 4 open problems]
- Data (own page): Every connected record, the notes, the JSON, Markdown and RDF twins, and where the record came from and when it was checked. https://onco.cc/cancers/ipmn-cystic-precursors/data/ [62 connected records]

## Standard of care

- Incidental cyst: Characterise with MRI and MRCP or pancreas-protocol CT; endoscopic ultrasound with fluid analysis when the cyst type is unclear or worrisome features are present. ([MRI](https://onco.cc/technologies/mri/), [CT (computed tomography)](https://onco.cc/technologies/ct/), [Endoscopic ultrasound and EBUS systems](https://onco.cc/technologies/endoscopic-ultrasound-systems/), [CA 19-9](https://onco.cc/terms/ca19-9/))
- High-risk stigmata: Resection (pancreatoduodenectomy or distal pancreatectomy) for obstructive jaundice, an enhancing mural nodule of 5 mm or more, a main duct of 10 mm or more, or positive cytology, in patients fit for surgery. ([Whipple procedure (pancreaticoduodenectomy)](https://onco.cc/terms/whipple/), [Obstructive jaundice and biliary obstruction](https://onco.cc/terms/obstructive-jaundice/), [Robotic & minimally invasive surgery](https://onco.cc/technologies/robotic-surgery/))
- Worrisome features: Endoscopic ultrasound and fluid sampling; resection or short-interval surveillance depending on findings, age and fitness. ([Endoscopic ultrasound and EBUS systems](https://onco.cc/technologies/endoscopic-ultrasound-systems/), [CA 19-9](https://onco.cc/terms/ca19-9/), [MRI](https://onco.cc/technologies/mri/))
- Surveillance: MRI or endoscopic ultrasound at intervals set by cyst size, continued while the patient remains a surgical candidate; the remaining pancreas is followed after resection. ([MRI](https://onco.cc/technologies/mri/), [High-risk pancreatic surveillance (CAPS / PRECEDE)](https://onco.cc/technologies/pancreatic-surveillance/), [Endoscopic ultrasound and EBUS systems](https://onco.cc/technologies/endoscopic-ultrasound-systems/))
- Invasive carcinoma in an IPMN: Staged and treated as pancreatic ductal adenocarcinoma with resection and adjuvant chemotherapy. ([Whipple procedure (pancreaticoduodenectomy)](https://onco.cc/terms/whipple/), [FOLFIRINOX / mFOLFIRINOX](https://onco.cc/drugs/folfirinox/), [PRODIGE 24 / CCTG PA6](https://onco.cc/trials/prodige-24/))

## State of the art

- Risk-stratified surveillance under the Fukuoka and Kyoto guidelines avoids surgery for the large majority of cysts.
- Cyst fluid mutation analysis separates mucinous from non-mucinous cysts and is entering routine use.
- Artificial intelligence reading of CT and MRI and blood-based markers aim to predict which cysts progress.
- The link between new-onset diabetes and early pancreatic cancer is being turned into a detection pathway.

## Open problems

- Most cysts never progress, and no test yet identifies the minority that will.
- Surveillance of a common incidental finding is costly and causes anxiety, and when it can safely stop is unknown.
- Surgery for cysts carries real morbidity, and a share of resected cysts turn out to be low grade.
- IPMN is a field disease, so cancer can arise elsewhere in the gland after resection.

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/Intraductal_papillary_mucinous_neoplasm
- Wikipedia: https://en.wikipedia.org/wiki/Intraductal_papillary_mucinous_neoplasm
- Kyoto guidelines for IPMN (Pancreatology 2024): https://doi.org/10.1016/j.pan.2023.12.009

## Connected records

- cancers: [Colloid (mucinous non-cystic) carcinoma of the pancreas](https://onco.cc/cancers/pancreatic-colloid-carcinoma/), [Invasive carcinoma arising in an intraductal papillary mucinous neoplasm (IPMN-associated carcinoma)](https://onco.cc/cancers/ipmn-associated-carcinoma/), [KRAS wild-type pancreatic ductal adenocarcinoma](https://onco.cc/cancers/kras-wild-type-pdac/), [Mismatch repair deficient (MSI-high) pancreatic ductal adenocarcinoma](https://onco.cc/cancers/msi-high-pdac/), [Mucinous cystic neoplasm of the pancreas with associated invasive carcinoma (MCN-associated carcinoma)](https://onco.cc/cancers/mcn-associated-carcinoma/), [Pancreatic acinar cell carcinoma](https://onco.cc/cancers/pancreatic-acinar-cell-carcinoma/), [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/), [Pancreatic neuroendocrine tumours](https://onco.cc/cancers/pancreatic-net/), [Resectable pancreatic ductal adenocarcinoma](https://onco.cc/cancers/resectable-pdac/), [Solid pseudopapillary neoplasm of the pancreas](https://onco.cc/cancers/solid-pseudopapillary-neoplasm/)
- roadmaps: [Early detection roadmap: organ screening → blood tests for many cancers](https://onco.cc/roadmaps/early-detection-roadmap/)
- technologies: [Comprehensive genomic profiling](https://onco.cc/technologies/cgp/), [CT (computed tomography)](https://onco.cc/technologies/ct/), [Endoscopic ultrasound and EBUS systems](https://onco.cc/technologies/endoscopic-ultrasound-systems/), [High-risk pancreatic surveillance (CAPS / PRECEDE)](https://onco.cc/technologies/pancreatic-surveillance/), [Liquid biopsy (ctDNA)](https://onco.cc/technologies/liquid-biopsy/), [MRI](https://onco.cc/technologies/mri/), [Multi-cancer early detection (MCED)](https://onco.cc/technologies/mced/), [Robotic & minimally invasive surgery](https://onco.cc/technologies/robotic-surgery/)
- targets: [KRAS](https://onco.cc/targets/kras/), [TP53](https://onco.cc/targets/tp53/)
- drugs: [FOLFIRINOX / mFOLFIRINOX](https://onco.cc/drugs/folfirinox/), [Galleri](https://onco.cc/drugs/galleri/)
- pathways: [p53 / RB / cell-cycle checkpoint](https://onco.cc/pathways/p53-cell-cycle/), [Pancreatic cancer (KEGG map)](https://onco.cc/pathways/pancreatic-cancer-signalling/), [Wnt / β-catenin](https://onco.cc/pathways/wnt/)
- terms: [CA 19-9](https://onco.cc/terms/ca19-9/), [Endoscopy (EGD, EUS, ERCP)](https://onco.cc/terms/endoscopy/), [Familial pancreatic cancer and inherited risk (who qualifies for surveillance)](https://onco.cc/terms/familial-pancreatic-cancer/), [Grade](https://onco.cc/terms/tumour-grade/), [High-risk stigmata and worrisome features of pancreatic cysts (IPMN and MCN surgical criteria)](https://onco.cc/terms/pancreatic-cyst-high-risk-stigmata/), [New-onset diabetes as a signal of pancreatic cancer (and the ENDPAC score)](https://onco.cc/terms/new-onset-diabetes-pancreatic-cancer/), [Obstructive jaundice and biliary obstruction](https://onco.cc/terms/obstructive-jaundice/), [Pancreas protocol CT (pancreatic protocol CT, dual-phase thin-slice CT with structured reporting)](https://onco.cc/terms/pancreas-protocol-ct/), [Pancreatic intraepithelial neoplasia (PanIN), the microscopic precursor of pancreatic cancer](https://onco.cc/terms/panin/), [Resectable, borderline resectable and unresectable](https://onco.cc/terms/resectability/), [Whipple procedure (pancreaticoduodenectomy)](https://onco.cc/terms/whipple/)
- people: [Anirban Maitra](https://onco.cc/people/anirban-maitra/), [Bert Vogelstein](https://onco.cc/people/bert-vogelstein/), [Diane M. Simeone](https://onco.cc/people/diane-simeone/), [Marc G. Besselink](https://onco.cc/people/marc-besselink/), [Richard Schulick](https://onco.cc/people/richard-schulick/)
- key papers: [A combination of molecular markers and clinical features improve the classification of pancreatic cysts](https://onco.cc/key-papers/paper-springer-pancreatic-cyst-molecular-classification-gastroenterology-2015/), [A revised classification system and recommendations from the Baltimore consensus meeting for neoplastic precursor lesions in the pancreas](https://onco.cc/key-papers/paper-basturk-baltimore-consensus-precursor-lesions-ajsp-2015/), [European evidence-based guidelines on pancreatic cystic neoplasms (2018)](https://onco.cc/key-papers/paper-european-evidence-based-guidelines-pancreatic-cystic-neoplasms-gut-2018/), [Genomic characterization of malignant progression in neoplastic pancreatic cysts](https://onco.cc/key-papers/paper-noe-cyst-malignant-progression-genomics-nat-commun-2020/), [International evidence-based Kyoto guidelines for the management of intraductal papillary mucinous neoplasm of the pancreas (2024)](https://onco.cc/key-papers/paper-kyoto-2024-evidence-based-guidelines-ipmn-pancreatology-2024/), [IPMNs with co-occurring invasive cancers: neighbours but not always relatives](https://onco.cc/key-papers/paper-felsenstein-ipmn-cooccurring-cancer-relatedness-gut-2018/), [Management of patients with increased risk for familial pancreatic cancer: updated recommendations from the International Cancer of the Pancreas Screening (CAPS) Consortium](https://onco.cc/key-papers/paper-caps-consortium-surveillance-recommendations-gut-2020/), [Pancreatic cancer early detection biomarkers for high-risk individuals: insights from the PRECEDE consortium](https://onco.cc/key-papers/paper-worthington-precede-early-detection-biomarkers-ijc-2026/), [Pancreatic intraepithelial neoplasia: a new nomenclature and classification system for pancreatic duct lesions](https://onco.cc/key-papers/paper-hruban-panin-nomenclature-ajsp-2001/), [Pathways of progression from intraductal papillary mucinous neoplasm to pancreatic ductal adenocarcinoma based on molecular features](https://onco.cc/key-papers/paper-omori-ipmn-progression-pathways-gastroenterology-2019/), [Precancerous neoplastic cells can move through the pancreatic ductal system](https://onco.cc/key-papers/paper-makohon-moore-precursor-cells-ductal-system-nature-2018/), [Presence of somatic mutations in most early-stage pancreatic intraepithelial neoplasia](https://onco.cc/key-papers/paper-kanda-panin-1-somatic-mutations-gastroenterology-2012/), [Recurrent GNAS mutations define an unexpected pathway for pancreatic cyst development](https://onco.cc/key-papers/paper-wu-gnas-ipmn-sci-transl-med-2011/), [Revised international consensus Fukuoka guidelines for the management of IPMN of the pancreas (2017)](https://onco.cc/key-papers/paper-fukuoka-2017-consensus-guidelines-ipmn-pancreatology-2017/), [Risk of Neoplastic Progression in Individuals at High Risk for Pancreatic Cancer Undergoing Long-term Surveillance](https://onco.cc/key-papers/paper-canto-caps-long-term-surveillance-gastroenterology-2018/), [Whole-exome sequencing of neoplastic cysts of the pancreas reveals recurrent mutations in components of ubiquitin-dependent pathways](https://onco.cc/key-papers/paper-wu-pancreatic-cyst-exomes-rnf43-pnas-2011/)
- ideas: [AI that spots pancreatic cancer on scans taken a year before diagnosis](https://onco.cc/ideas/idea-prev-pancreas-ai-prediagnostic-ct/), [Blood-based pancreatic cancer detection in new-onset diabetes](https://onco.cc/ideas/idea-mced-new-onset-diabetes/), [Glucose monitor data as an early pancreatic cancer signal](https://onco.cc/ideas/idea-prev-cgm-glycaemic-drift-pancreas/), [New diabetes after 50 plus weight loss triggers a pancreatic cancer check](https://onco.cc/ideas/idea-prev-new-onset-diabetes-pancreas-pathway/), [Stop watching stable low-risk pancreatic cysts after five years](https://onco.cc/ideas/idea-prev-ipmn-surveillance-stop-rule/)
- trials: [EUROPAC](https://onco.cc/trials/europac/), [PRECEDE](https://onco.cc/trials/precede/), [PRODIGE 24 / CCTG PA6](https://onco.cc/trials/prodige-24/)

---
JSON: https://onco.cc/api/v1/entities/ipmn-cystic-precursors.json